Clinical Trial Update: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase Ib safety study of trastuzumab deruxtecan in combination with immunotherapy agents, with or without chemotherapy, f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 1 | Status: RECRUITING